5VM

5AM Venture Management Portfolio holdings

AUM $288M Turnover 20%
1-Year Est. Return 313.93%
This Fund
S&P 500
This Quarter Est. Return
+71.58%
1 Year Est. Return
+313.93%
3 Year Est. Return
+546.33%
5 Year Est. Return
+596.42%
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$42.1M
Cap. Flow
-$52.8M
Cap. Flow %
-14.65%
Top 10 Hldgs %
79.82%
Holding
22
New
1
Increased
–
Reduced
2
Closed
2
Avg Time Held
2.1 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$5.82M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$22.9M
2
ERAS icon
Erasca
ERAS
+$22.7M
3
ELVN icon
Enliven Therapeutics
ELVN
+$11.9M
4
RLYB icon
Rallybio
RLYB
+$1.11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ERAS icon
1
Erasca
ERAS
$5.14B
$56.4M 15.66%
3,485,971
-1,919,433
-36% -$22.7M
2024 Q2
7 quarters
TRDA icon
2
Entrada Therapeutics
TRDA
$177M
$51.2M 14.21%
4,056,379
– –
2021 Q4
17 quarters
TYRA icon
3
Tyra Biosciences
TYRA
$1.29B
$39.4M 10.94%
1,029,298
– –
2023 Q3
10 quarters
CAMP icon
4
CAMP4 Therapeutics
CAMP
$215M
$25.9M 7.19%
5,869,091
– –
2024 Q4
5 quarters
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$23.1M 6.41%
580,945
– –
2024 Q1
8 quarters
PHVS icon
6
Pharvaris
PHVS
$2.11B
$22.5M 6.26%
797,600
– –
2022 Q2
15 quarters
MPLT icon
7
MapLight Therapeutics
MPLT
$434M
$19.3M 5.36%
950,011
– –
2025 Q4
1 quarter
TECX icon
8
Tectonic Therapeutic
TECX
$410M
$18.8M 5.21%
606,660
– –
2024 Q2
7 quarters
CLDX icon
9
Celldex Therapeutics
CLDX
$2.19B
$15.8M 4.38%
497,270
– –
2023 Q2
11 quarters
ARTV icon
10
Artiva Biotherapeutics
ARTV
$289M
$15.2M 4.21%
2,353,304
– –
2024 Q3
6 quarters
EYPT icon
11
EyePoint Inc
EYPT
$259M
$13.5M 3.76%
1,050,000
– –
2024 Q2
7 quarters
SRZN icon
12
Surrozen
SRZN
$279M
$11.3M 3.13%
387,500
– –
2025 Q1
4 quarters
ZNTL icon
13
Zentalis Pharmaceuticals
ZNTL
$220M
$9.24M 2.56%
3,947,913
– –
2023 Q2
11 quarters
GHRS icon
14
GH Research
GHRS
$1.27B
$8.05M 2.24%
572,665
– –
2023 Q2
11 quarters
TARA icon
15
Protara Therapeutics
TARA
$147M
$7.14M 1.98%
1,369,782
– –
2024 Q4
5 quarters
BHVN icon
16
Biohaven
BHVN
$1.65B
$6.25M 1.74%
738,972
– –
2023 Q4
9 quarters
ALXO icon
17
ALX Oncology
ALXO
$124M
$6.13M 1.7%
+3,057,325
New +$5.82M
2026 Q1
0 quarters
SKYE icon
18
Skye Bioscience
SKYE
$6.95M
$5.95M 1.65%
1,210,220
– –
2024 Q2
7 quarters
RLYB icon
19
Rallybio
RLYB
$89.8M
$2.62M 0.73%
291,788
-162,053
-36% -$1.11M
2021 Q3
18 quarters
SLN icon
20
Silence Therapeutics
SLN
$558M
$2.51M 0.7%
476,200
– –
2024 Q1
8 quarters
ELVN icon
21
Enliven Therapeutics
ELVN
$2.88B
– –
-772,477
Closed -$11.9M –
VRDN icon
22
Viridian Therapeutics
VRDN
$2.08B
– –
-736,595
Closed -$22.9M –

Similar funds

TA
TKG Advisors Valparaiso, Indiana $288M AUM 43.58% 1-Year Est. Return
APW
Alliance Private Wealth North Reading, Massachusetts $288M AUM
RCS
Retirement Capital Strategies San Jose, California $288M AUM 17.43% 1-Year Est. Return
FH
FWG Holdings Winter Park, Florida $288M AUM 33.26% 1-Year Est. Return
IAMOG
Investors Asset Management of Georgia Atlanta, Georgia $288M AUM 47.58% 1-Year Est. Return
MP
Maestria Partners Atlanta, Georgia $288M AUM 13.77% 1-Year Est. Return
OL
Owen LaRue Elizabethtown, Kentucky $288M AUM 29.4% 1-Year Est. Return
CFG
Cambridge Financial Group Columbus, Ohio $287M AUM 33.96% 1-Year Est. Return

5AM Venture Management's Q1 2026 Portfolio in Review

As of Q1 2026, 5AM Venture Management held 22 positions worth $360M, up 13% from $318M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

5AM Venture Management withdrew a net $52.8M in Q1 2026, closing 2 positions and reducing 2 holdings. Its most notable exit was Viridian Therapeutics, an estimated $22.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, 5AM Venture Management opened a new position in ALX Oncology worth $6.13M.

  • 5AM Venture Management's largest Q1 2026 buy was ALX Oncology: 3,057,325 shares worth $6.13M.
  • 5AM Venture Management's biggest Q1 2026 reduction was Erasca, cutting an estimated $22.7M.
  • 5AM Venture Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $22.9M.
  • 5AM Venture Management's ten largest holdings make up 80% of its $360M portfolio in Q1 2026.
  • 5AM Venture Management opened 1 new position and closed 2 in Q1 2026.
  • 5AM Venture Management's portfolio value rose 13% quarter-over-quarter to $360M.

Based on 5AM Venture Management's 13F filing for Q1 2026, filed 15 May 2026.